Company profile
OKYO PHARMA LTD
NASDAQ:OKYOBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| URCOSIMOD | phase2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07838506 | phase3 | not_yet_recruiting | 2026-09-01 | 2027-05-01 | Okyo Pharma Ltd | Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP). |
| NCT06637527 | phase2 | terminated | 2024-10-15 | 2025-04-30 | Okyo Pharma Ltd | The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain |
| NCT05759208 | phase2 | completed | 2023-04-28 | 2023-12-15 | Okyo Pharma Ltd | The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease |
FDA applications (0)
No records yet.